The simple version
Binge eating disorder is now part of early psilocybin research. That does not mean psilocybin has been proven to treat it.
A 2026 open-label pilot study followed five adults with binge eating disorder. The study reported fewer self-reported binge eating episodes after psilocybin-assisted therapy, along with no serious adverse events. But the authors also made the key limitation clear: because the study was very small and open-label, cause and effect cannot be proven. [1] Clinical trial An open-label pilot study of psilocybin-assisted therapy for binge eating disorder doi:10.1186/s40337-025-01508-3
That is the entire story in one sentence: early signal, not proof.
What binge eating disorder means
Binge eating disorder is not simply eating more than planned. NIMH describes binge-eating disorder as regularly losing control of eating and eating unusually large amounts of food. [2] Government Eating Disorders: What You Need to Know Link → The experience can involve distress, shame, secrecy, anxiety, depression, and a painful cycle of trying to regain control.
That makes this a mental health and medical issue, not a willpower issue. It also means research needs to avoid shame-based language. Public education must not tell people to “just stop,” “just control it,” or “just try mushrooms.” None of that is responsible.
Why researchers are looking at psilocybin
Researchers are interested because binge eating can involve repeated loops: urge, loss of control, relief, shame, and trying again. Some psychedelic researchers are studying whether supported therapy may help people relate differently to rigid or automatic patterns.
The 2026 pilot study paired psilocybin with therapy based on acceptance and commitment therapy, often called ACT. In plain English, that means the study was not only about the substance. It also included psychological work around values, patterns, and behavior. [1] Clinical trial An open-label pilot study of psilocybin-assisted therapy for binge eating disorder doi:10.1186/s40337-025-01508-3
Why the study is still very early
A study with five people is not enough to prove a treatment. An open-label study also has a major limitation: people know what they are receiving. That can affect expectations, reporting, motivation, and the meaning people give to changes.
That does not make the study useless. It makes it a starting point. Small pilot studies help researchers decide whether larger and more controlled research is worth doing. They do not give the public permission to turn the result into a claim.
What changed in the pilot study
The study reported reductions in self-reported binge eating across the participants and improvements in some related measures such as anxiety, depression, and psychological flexibility. It also reported no serious adverse events in that small sample. [1] Clinical trial An open-label pilot study of psilocybin-assisted therapy for binge eating disorder doi:10.1186/s40337-025-01508-3
Those findings are worth tracking. But the safest wording is still: researchers observed improvements in a small early study. The study did not prove that psilocybin caused those improvements.
Why body weight is not the point
Binge eating disorder can be tangled up with body image, shame, dieting history, weight stigma, and medical concerns. But an education page must not reduce the topic to weight.
The more useful focus is suffering, loss of control, health, safety, and access to qualified care. NIMH notes that people with eating disorders can have different body weights and may appear healthy even when they are very ill. [2] Government Eating Disorders: What You Need to Know Link →
What this does not mean
This article does not recommend psilocybin for binge eating disorder. It does not give instructions. It does not claim microdosing helps binge eating. It does not suggest leaving therapy, nutrition care, or medical care.
It means the research is early enough to explain and sensitive enough to explain carefully.
The bottom line
The binge eating research is small but important. It gives researchers a reason to keep studying the question.
For the public, the right takeaway is simple: interesting early data, no proven treatment claim, no self-treatment advice.
Why therapy around the session matters
The BED pilot did not test psilocybin as an isolated event. It placed the session inside a therapy model. That matters because the therapy may help people notice urges, values, emotions, avoidance, and old patterns in a different way.
The broader 2025 review of psilocybin and eating-disorder research also treats this as an early clinical research area, not a ready public treatment lane. [3] Systematic review Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials doi:10.1007/s40519-025-01771-y
Why this can be hopeful without being hype
People with binge eating disorder may feel exhausted by cycles of control and loss of control. A small early study can feel hopeful because it suggests researchers are taking the condition seriously and testing new models.
But hope needs guardrails. A five-person study cannot tell us what happens across ages, genders, body sizes, medical histories, trauma histories, medication backgrounds, or longer follow-up. It cannot tell us whether the same result would happen without therapy support. NCCIH’s broader psilocybin guidance also emphasizes the role of support and setting in psychedelic-assisted therapy. [4] Government Psilocybin for Mental Health and Addiction: What You Need To Know Link →
That is why the public copy must stay balanced.